Antiphospholipid antibodies (aPL) have been associated with a variety of neurological disorders, mostly linked to focal neuroparenchymal ischemia or infarction. Cerebral ischemia associated with the antiphospholipid syndrome (APS) occurs at a younger age than typical atherothrombotic cerebrovascular disease, is often recurrent, and high positive GPL values are usually linked to the presence of a lupus anticoagulant. When other features of the syndrome are not present and cerebral ischemia occurs only associated with anticardiolipin immunoreactivity, there appears to be no discerning features of these patients unless GPL > 40 for which recurrent thrombo-occlusive events appear to occur more frequently. Other neurological manifestations associated with aPL include cerebral venous sinus thrombosis, ocular ischemia, dementia, including ischemic encephalopathy, and chorea. The role of aPL in migrainous events is controversial and may not play a role in recent, large case-controlled studies. Most seizures in patients harboring aPL are associated with focal brain infarction.
VilaPHernandezMCLopez-FernandezMFBatlleJ. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemostat1994; 72: 209–213
2.
McNeilHPChestermanCNKrilisSA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol1991; 49: 193–280
3.
CoullBMLevineSRBreyRL. The role of antiphospholipid antibodies and stroke. Neurol Clin1992; 10: 125–143
4.
FeldmannELevineSR. Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance and therapeutic options. Ann Neurol1995; 37 (Suppl 1): S114–S130
5.
LevineSRRecurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol1995; 38: 119–124
6.
CampbellALPierangeliSSWellhausenSHarrisEN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome and with syphilis on platelet activation and aggregation. Thromb Haemostat1995; 73: 529–534
7.
Vasquez-MelladoJLlorenteLRichaud-PatinYAlarcon-SegoviaD. Exposure of anionic phospholipids upon platelet activation permits binding of beta-2-glycoprotein I and through it that of IgG antiphospholipid antibodies. J Autoimmunity1994; 7: 335–348
8.
BreyRLLevineSR. Treatment of neurologic complications of the antiphospholipid antibody syndrome. Lupus1996; 5: 473–476
9.
Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology1993; 43: 2069–2073
10.
CamerlingoMAnticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand1995; 92: 60–71
11.
BreyRLHartRGShermanDGTegelerCT. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology1990; 40: 1190–1196
12.
LevineSRDeeganMJFutrellNWelchKMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology1990; 40: 1190–1196
13.
MontalbanJValue of immunologic testing in stroke patients: a prospective multicenter study. Stroke1994; 25: 2412–2415
14.
GinsburgKSAnticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med1992; 117: 997–1002
CioccaRGChoiJGrahamAM. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg1995; 170: 198–200
17.
D'OlhaberriagueLSpecificity of anticardiolipin antibodies in cardiovascular diseases. Lupus1996 (in press)
18.
The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke1990; 21: 1268–1273
19.
FordSELillicrapDMBrunetDFordPM. Thrombotic endocarditis and lupus anticoagulant, a pathogenetic possibility for idiopathic rheumatic type valvular heart disease. Arch Pathol Lab Med1989; 113: 350–353
20.
KhamashtaMAAssociation of antibodies against phospholipids with valvular heart disease in patients with systemic lupus erythematosus. Lancet1990; 335: 1541–1544
21.
CerveraRHigh prevalence of significant heart valve lesions in patients with the ‘primary’ antiphospholipid antibody syndrome. Lupus1991; 1: 43–47
22.
BaduiEThe heart in the primary antiphospholipid syndrome. Arch Med Res1995; 26: 115–120
RosoveMHBrewerPMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med1992; 117: 303–308
27.
TriplettDABrandtJTMusgraveKAOrrCA. The relationship between lupus anticoagulants and antibodies to phospholipids. JAMA1988; 259: 550–554
28.
Alarcon-SegoviaDAntiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine1989; 68: 353–365
29.
VerroPLevineSRTietjenGE. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke1995; 26: 160
30.
EscalanteABreyRLMitchellBDDreinerU. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med1995; 98: 559–567
31.
CarhuapomaJRMitsiasPLevineSR. The association of cerebral venous thrombosis with anticardiolipin antibodies. Neurology1996; 46: A458
32.
BokarewaMIStudies on antiphospholipid antibodies. APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res1995; 78: 193–200
33.
Del PapaNRelationship between antiphospholipid and antiendothelial cell antibodies III: beta-2-glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheum1995; 13: 179–185
34.
PierangeliSSHarrisEN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus1994; 3: 247–251
35.
RafusePECannyCLB. Initial identification of antinuclear antibody-negative systemic lupus erythematosus on ophthalmic examination: a case report with discussion of the ocular significance of anticardiolipin (antiphospholipid) antibodies. Can J Ophthalmol1992; 27: 189–193
36.
LabuttaRJ. Ophthalmic manifestations in the antiphospholipid syndrome. In: AshersonRACerveraRPietteJCShoenfeldY(eds) The Antiphospholipid Syndrome. CRC Press, 1996, 213–218, USA
37.
KalashnikovaLANasonovELKushekbaevaAEGrachevaLA. Anticardiolipin antibodies in Sneddon's syndrome. Neurology1990; 40: 464–467
ZelzerBSneddon's syndrome: A long term follow-up of 21 patients. Arch Dermatol1993; 129: 437–444
40.
CoullBMMultiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke1987; 18: 1107–1112
41.
SchmidtRAnticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke1995; 26: 749–754
42.
TietjenGEFactors which predict antiphospholipid immunoreactivity in young people with focal neurologic deficits. Arch Neurol1993; 50: 833–836
43.
TietjenGEDifferentiating TIA from migraine aura in adults under 60 years of age. Stroke1995; 26: 174
44.
SilvestriniMMigrainous stroke and the antiphospholipid antibodies. Eur Neurol1994; 34: 316–319
45.
TietjenGE, unpublished data, personal communication, 1996.
46.
HerranzMTAssociation between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum1994; 37: 586–571
47.
InzelbergRKorczynAD. Lupus anticoagulant and late onset seizures. Acta Neurol Scand1989; 79: 114–118
48.
LevineSRWelchKMA. The spectrum of neurologic disease associated with antiphospholipid antibodies: lupus anticoagulants and anticardiolipin antibodies. Arch Neurol1987; 44: 876–883
49.
LiouHHAnticardiolipin antisera from lupus patients with seizures reduce a gaba receptor-medicated chloride current in snail neurons. Life Sciences1994; 54: 1119–1125
YehTSThe study of anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with systemic lupus erythematosus and central nervous system involvement. Autoimmunity1994; 18: 169–175
52.
BreyRLCoteSTealeJM. Neurological dysfunction and autoantibody-producing B cells from brain in a lupus-prone mouse strain. Neurology1993; 44: 1420
53.
AshersonRAHughesGRV, Antiphospholipid antibodies and chorea. J Rheumatol1988; 15: 377–379
FurieRIshikawaTDhawanVEidelbergD. Alternating hemichorea in primary antiphospholipid syndrome: evidence for contralateral striatal metabolism. Neurology1994; 44: 2197–2199
56.
MontalbanJTransient global amnesia and antiphospholipid antibodies. Clin Exp Rheumatol1989; 7: 85–87
57.
HarrisENLupoid sclerosis: a possible pathogenic role for antiphospholipid antibodies. Ann Rheum Dis1985; 44: 281–283
58.
LavalleCTransverse myelitis: a manifestation of systemic lupus erythematosus associated with antiphospholipid antibodies. J Rheumatol1990; 17: 34–37
59.
JacksonCAnticardiolipin antibodies in Guillain-Barre Syndrome. Clin Exp Rheumatol1992; 10: 657
60.
HarrisENAntiphospholipid antibodies in acute guillain-barre syndrome. Lancet1983; 2: 1361–1362
61.
MaesMAntiphospholipid antibody, epstein barr and cytomegalovirus antibodies and interleukin-2 receptors in depressive patients. J Affective Dis1991; 21: 133–140
62.
MoladYLupus anticoagulant correlation with magnetic resonance imaging of brain lesions. J Rheumatol1992; 19: 556–561
63.
ProvenzaleJMAntiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiologic findings. Radiology1994; 192: 531–537
64.
ToubiEKhamashtaMAPanarraAHughesGRV. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med1995; 99: 397–401
65.
D'OlhaberriagueLLevineSRTietjenGEAuroraT. Embolism is the most likely mechanism of stroke related to antiphospholipid antibodies. Neurology1996; 46: 459
